



NDA 020639/S-064
NDA 022047/S-038

SUPPLEMENT APPROVAL

AstraZeneca pharmaceuticals LP
U.S. Agent for AstraZeneca UK Limited
Attention: Robert Griffin
Global Regulatory Affairs Director
1800 Concord Pike
Wilmington, DE 19803

Dear Mr. Griffin:

Please refer to your Supplemental New Drug Applications (sNDAs) dated June 9, 2016, received June 9, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Seroquel (quetiapine fumarate) 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg tablets (NDA 20639/S-064) and Seroquel XR (quetiapine fumarate) Extended-Release 50 mg, 150 mg, 200mg, 300 mg and 400 mg tablets (NDA 22047/S-038).

We also refer to our letter dated May 10, 2016, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for Seroquel and Seroquel XR. This information pertains to the risk of an association between quetiapine and drug reaction with eosinophilia and systemic symptoms (DRESS).

These supplemental new drug applications provide for revisions to the labeling for Seroquel and Seroquel XR, consistent with our May 10, 2016 letter.

APPROVAL & LABELING

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Danbi Lee, Regulatory Project Manager, at (240) 402-8986.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, MD
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
06/17/2016